Structure Therapeutics (NASDAQ:GPCR – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 77.89% from the stock’s current price.
Separately, Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $85.71.
Check Out Our Latest Stock Report on Structure Therapeutics
Structure Therapeutics Trading Down 1.4 %
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. Equities analysts expect that Structure Therapeutics will post -0.98 EPS for the current year.
Hedge Funds Weigh In On Structure Therapeutics
Several institutional investors have recently bought and sold shares of GPCR. Wellington Management Group LLP lifted its holdings in shares of Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after acquiring an additional 3,504,747 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after acquiring an additional 1,607,525 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after acquiring an additional 1,333,333 shares during the last quarter. FMR LLC bought a new stake in shares of Structure Therapeutics in the 1st quarter worth about $29,724,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after acquiring an additional 1,157,006 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.
Structure Therapeutics Company Profile
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Read More
- Five stocks we like better than Structure Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Steel Stocks Could Soar on New China Tariffs
- Consumer Staples Stocks, Explained
- Bear Market Funds to Watch This Year
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.